Regulatory approval
Published by the Health Canada. Approved
IBRANCE (palbociclib) is indicated for the treatment of pre/perimenopausal or postmenopausal women, or men with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor as initial endocrine-based therapy.
This is written in the approval document.
Citation
Therapeutic response
Precision oncology relationships for therapeutic response derived from this regulatory approval.
| Organizations | Biomarkers | Cancer types | Therapies | |
|---|---|---|---|---|
| HC (1) | ER positive, HER2-negative | Invasive Breast Carcinoma | Letrozole, Palbociclib | |
| HC (1) | HER2-negative, PR positive | Invasive Breast Carcinoma | Letrozole, Palbociclib | |
| HC (1) | ER positive, HER2-negative, PR positive | Invasive Breast Carcinoma | Letrozole, Palbociclib |